MedAI Intelligence Completes Series C Funding Round, Secures Second Investment Within Three Months as Medical AI Commercialization Accelerates

On June 21, Beijing Medical Standard Intelligent Technology Co., Ltd. (hereinafter referred to as “MEDICAL AI”) announced the completion of a new round of Series C financing. The round was led by Boyuan Capital, with Shengyu Investment participating as a co-investor, and Haneng Investment serving as the exclusive financial advisor. The proceeds from this financing will be used to increase investment in the research and development of existing technologies, continuously improve its comprehensive, intelligent, multi-device AI product matrix, accelerate the deployment of its products across medical institutions at all levels, and promote the full coverage of smart hospital construction.

Notably, MEDICAL AI has completed its second round of financing this year, just three months after the previous round. The company’s total fundraising in the first half of 2021 has reached hundreds of millions of RMB. This series of rapid financings within a short period fully demonstrates MEDICAL AI’s core competitiveness and investment value, while also reflecting investors’ expectations for the commercialization prospects of its AI-powered medical imaging solutions.

The “Proposal of the Central Committee of the Communist Party of China on Formulating the 14th Five-Year Plan for National Economic and Social Development and the Long-Range Objectives Through the Year 2035” explicitly emphasizes promoting the deep integration of the internet, big data, artificial intelligence, and other technologies with various industries. Amid this trend, “medical AI” has garnered particularly high attention.

Boyuan Capital, the lead investor in this round, is a specialized investment firm dedicated to investing in and incubating outstanding healthcare startups in China. It has assembled an investment team comprising professionals from healthcare startups, leading domestic biotechnology companies, multinational pharmaceutical corporations, and professional service firms in the healthcare sector, demonstrating exceptional foresight and sensitivity to the healthcare industry.

Chen Penghui, Partner at Boyuan Capital, stated: “As a professional investment firm focused on healthcare, Boyuan Capital has always believed in the transformation and opportunities brought by digitalization and intelligence to the medical field, and we are committed to exploring ways to create greater value for the healthcare industry. We are delighted to witness the breakthroughs achieved by MEDICAL AI in the field of medical artificial intelligence. MEDICAL AI is one of the few companies in China that has solidly developed multi-disease imaging AI solutions. Its multi-disease chest CT AI product has seen rapid revenue growth. Its proprietary full-stack breast AI solution covers examination scenarios including mammography, breast tomosynthesis, and breast ultrasound, achieving full-stack AI empowerment for breast cancer screening. Such solutions are leading on a global scale. We look forward to partnering with MEDICAL AI to create more value for patients, society, and the nation.”

MEDICAL AI empowers healthcare through artificial intelligence technology. By leveraging technological innovation and exploration, it has established a comprehensive product ecosystem for AI-assisted analysis and a robust research infrastructure. Grounded in real-world clinical needs, MEDICAL AI has developed a full-spectrum portfolio of AI-based imaging assistance products tailored to diverse application scenarios, disease types, and imaging equipment. It offers systematic solutions covering multiple anatomical regions—including the chest, breast, and coronary arteries—and compatible with various devices. Notable offerings include a full-stack intelligent breast imaging solution that spans from screening management to diagnostic analysis, as well as a multi-disease intelligent solution for chest CT scans addressing eight major conditions. By launching this multidimensional product matrix and forging close partnerships with hardware manufacturers, MEDICAL AI comprehensively accelerates the implementation of smart healthcare solutions.

Full-Stack Intelligent Breast Analysis Solution

Shen Qin, Partner at Shengyu Investment, stated: “In recent years, artificial intelligence has flourished across the healthcare sector. MEDICAL AI’s suite of solutions, enabling multi-device applications, has assisted over 600 medical institutions at various levels in performing imaging-based auxiliary analysis for tens of millions of patients, achieving ‘enhanced efficiency and improved quality.’ Furthermore, by providing precise support to physicians in detection and analysis across diverse scenarios—including radiology departments and clinical specialties—MEDICAL AI is comprehensively reshaping health management processes from examination and diagnosis to analysis and treatment, thereby delivering ‘high efficiency and precision.’”

MEDICAL AI delves deeply into diagnostic and treatment logic, maintaining strategic focus with a cross-cutting approach. Horizontally, it covers every imaging product and device. Vertically, starting from single diseases and single body parts, it extends from imaging diagnosis to clinical treatment, comprehensively enhancing the quality and efficiency of every link in the clinical pathway, thereby creating a full-process, intelligent AI overall solution for physicians.